![Diagnosing acute intestinal graft-versus-host disease by a non-invasive method: transabdominal ultrasonography and colour doppler imaging - The Lancet Diagnosing acute intestinal graft-versus-host disease by a non-invasive method: transabdominal ultrasonography and colour doppler imaging - The Lancet](https://www.thelancet.com/cms/attachment/72d041dd-7558-46b4-88ba-5f266bcc8f9d/gr1_lrg.jpg)
Diagnosing acute intestinal graft-versus-host disease by a non-invasive method: transabdominal ultrasonography and colour doppler imaging - The Lancet
![Examining Potential Biomarkers for Early Detection of Chronic Graft-Versus-Host Disease - Docwire News Examining Potential Biomarkers for Early Detection of Chronic Graft-Versus-Host Disease - Docwire News](https://www.docwirenews.com/wp-content/uploads/2022/04/3058-2-4-scaled.jpg)
Examining Potential Biomarkers for Early Detection of Chronic Graft-Versus-Host Disease - Docwire News
![EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect? EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?](https://i.ytimg.com/vi/YbEjV7XspMI/maxresdefault.jpg)
EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?
![Scientific Education Support | GvHD Hub Press Release Q1: The Gvhd Hub in Q1 2022: Boosting Levels Of Knowledge In The Graft-Versus-Host Disease Setting Through Key Updates And Congress Coverage Scientific Education Support | GvHD Hub Press Release Q1: The Gvhd Hub in Q1 2022: Boosting Levels Of Knowledge In The Graft-Versus-Host Disease Setting Through Key Updates And Congress Coverage](https://mytest.nyc3.digitaloceanspaces.com/ses2021cms/prod/7a91fa6404c47c1344cd306d0a9f273f.png)
Scientific Education Support | GvHD Hub Press Release Q1: The Gvhd Hub in Q1 2022: Boosting Levels Of Knowledge In The Graft-Versus-Host Disease Setting Through Key Updates And Congress Coverage
![P-BCMA-ALLO1 receives clearance of investigational new drug application by FDA for the treatment of multiple myeloma P-BCMA-ALLO1 receives clearance of investigational new drug application by FDA for the treatment of multiple myeloma](https://multiplemyelomahub.com/media/images_resized/22/d0/mm-hub-website-graphic-orphan-drug[ogImageMetaTag].jpg)